This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

49/100

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

The prevalence of PIMcogs increased from 16% at baseline to 23% at follow-up. PIMcog users were more likely to be women (63.5%), and they used more drugs, with a median of 5 drugs at baseline and 4 drugs at follow-up, compared to non-users who had a median of 3 used drugs at both time points. PIMcog users had higher median Neuropsychiatric Inventory severity sum scores (6 [3.0–11.0] versus 4.0 [2.0–7.0]) and median Cornell Scale for Depression in Dementia scores (6.5 [3.0–11.0] versus 4.0 [1.0–7.0]) compared to non-users at follow-up (p ≤ 0.002). PIMcog users exhibited more severe dementia, with a Clinical Dementia Rate-Sum of Boxes (CDR-SB) score of 7.0 (4.0–13.0) compared to 6.0 (3.5–10.0) in non-users. The median annual increase in CDR-SB was one unit, and PIMcog use at follow-up was significantly associated with more rapid progression of dementia severity. Faster dementia progression was documented among PIMcog users although, the prevalence of PIMcogs was generally low in Norwegian memory clinic patients with cognitive impairments.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kersten, H., Barca, M. L., Eldholm, R. S., Persson, K., Thomasgaard, L., Jaioun, K., et al. (2026). Potentially inappropriate medications related to two-year progression of mild cognitive impairment and dementia. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03977-6

Vancouver

Kersten H, Barca ML, Eldholm RS, Persson K, Thomasgaard L, Jaioun K, et al. Potentially inappropriate medications related to two-year progression of mild cognitive impairment and dementia. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-025-03977-6. PMID: 41553533.

BibTeX

@article{kersten2026-41553533,
  author  = {Kersten, Hege and Barca, Maria Lage and Eldholm, Rannveig Sakshaug and Persson, Karin and Thomasgaard, Lara and Jaioun, Keson and Saltvedt, Ingvild Tina and Selbæk, Geir and others},
  title   = {{Potentially inappropriate medications related to two-year progression of mild cognitive impairment and dementia}},
  journal = {European Journal of Clinical Pharmacology},
  year    = {2026},
  doi     = {10.1007/s00228-025-03977-6},
  pmid    = {41553533},
  url     = {https://doi.org/10.1007/s00228-025-03977-6}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

The prevalence of PIMcogs increased from 16% at baseline to 23% at follow-up.
PIMcog users were more likely to be women (63.5%), and they used more drugs, with a median of 5 drugs at baseline and 4 drugs at follow-up, compared to non-users who had a median of 3 used drugs at both time points.
PIMcog users had higher median Neuropsychiatric Inventory severity sum scores (6 [3.0–11.0] versus 4.0 [2.0–7.0]) and median Cornell Scale for Depression in Dementia scores (6.5 [3.0–11.0] versus 4.0 [1.0–7.0]) compared to non-users at follow-up (p ≤ 0.002).
PIMcog users exhibited more severe dementia, with a Clinical Dementia Rate-Sum of Boxes (CDR-SB) score of 7.0 (4.0–13.0) compared to 6.0 (3.5–10.0) in non-users.
The median annual increase in CDR-SB was one unit, and PIMcog use at follow-up was significantly associated with more rapid progression of dementia severity.

Why it matters

Use of potentially inappropriate medications for cognition at follow-up was significantly associated with more rapid progression of dementia severity. This is an observational association and does not test any treatment, cure or prevention.

Study details

Participants397
Effect size63.5%
Evidence strengthLow

How this study scored 49/100

Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (European Journal of Clinical Pharmacology)
Journal's citation record	2 / 4	European Journal of Clinical Pharmacology: journal h-index 161 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	2 / 4	397 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.5 citations a year over 2 year(s) since 2026
Impact for its field and year	4 / 6	Cited 11.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Knut Engedal: h-index 72 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Oslo: institution h-index 1,024 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41553533)
Free to read	2 / 2	Free to read
Total	49 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment

Also tagged “examination”

840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →